German Court Finds ArthroVision's Patent Not Infringed by Chondrometrics

MONTREAL, QUEBEC, Apr 03 (MARKET WIRE) --
ArthroVision Inc., a wholly-owned subsidiary of Horizon Sciences &
Technologies Inc., announced today that the District Court of Munich,
Germany, decided that Chondrometrics GmbH has not infringed on the German
part of ArthroVision's patent EP 1 230 561. The patent relates to
evaluating disease progression by means of magnetic resonance imaging.
The Court determined that Chondrometrics software would not make use of
claims 1 and 11 of the patent.

ArthroVision plans to promptly appeal in full the not yet final District
Court's infringement decision. ArthroVision executive officers believe
that the first instance judgment of the Munich District Court will be
corrected on appeal. ArthroVision is committed to globally protecting its
intellectual property.

About Horizon Sciences & Technologies and ArthroVision Inc.

Horizon Sciences & Technologies Inc., a Canadian biopharmaceutical
company located in Montreal, Quebec, Canada, is involved, in
collaboration with its partners, in the discovery and development of new
and innovative technologies for the prevention, the diagnosis and the
treatment of osteoarthritis. Its subsidiary, ArthroVision Inc., a
Montreal, Quebec, based company, is engaged in the research and
development of imaging technology to assess the effect of therapeutics in
the treatment of osteoarthritis. ArthroVision has developed imaging
systems that allow the precise measurement and quantification of
cartilage from magnetic resonance images (MRIs) and the tracking of
cartilage degradation over time. These technologies represent a
breakthrough for osteoarthritis research. ArthroVision has extensive
expertise in conducting clinical trials for the assessment of the
efficacy of new drugs and compounds that aim at reducing the progression
of osteoarthritis.

Forward-Looking Statements

This press release contains "forward looking information" (as defined in
applicable Canadian securities legislation) that are based on
expectations, estimates and projections as of the date of this press
release. Often, but not always, such forward looking information can be
identified by the use of forward looking words such as "plans", "expects"
or "does not expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or
"believes", or variations of such words and phrases or statements that
certain actions, events or results "may", "could", "would", "might" or
"will" be taken, occur or be achieved. Forward looking information
involves known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements to be
materially different from any future results, performance or achievements
expressed or implied by the forward looking information in this press
release. Examples of such forward looking information in this press
release include, but are not limited to, factors relating to the possible
appeal of first instance judgment of the Munich District Court, which is
subject to significant risks and uncertainties, including the possibility
that Court of Appeal may not find in favour of ArthroVision Inc. Actual
results are likely to differ, and may differ materially, from those
expressed or implied by the forward looking information contained in this
press release. There can be no assurance that forward looking information
will prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward looking information.

Contacts:
Horizon Sciences & Technologies inc.
Bertrand Masse, CA
Chief Financial Officer
514-890-8000 ext. 28915

Copyright 2009, Market Wire, All rights reserved.

-0-